Public Comment on OMB Draft Risk Assessment Bulletin

The OIRA draft Risk Assessment Bulletin has worthy intentions and has stimulated useful review and discussion.; Most previous major documents in the development of the risk assessment field have been cited and used appropriately. In general, the formulation is too broad. The Revision should clarify the place of risk assessment as distinguished from hazard identification and from risk management.The category of "influential risk assessment" is unnecessary and confusing, and should be deleted. A single set of six standards would suffice, without the additional nine special standards for "influential risk assessments". Greater transparency within the EOP is desirable to give this process credibility and meet one of the explicit aims of the Bulletin. Finally, several omissions should be addressed: proactive engagement of stakeholders, public health context, deceptive use of quantitation, exclusion for research agencies, interagency steering committee and symmetry of risk assessment guidance for manufacturers as well as regulatory agencies.

The human eye proteome project

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/99592/1/pmic7517.pd

A landmark systems analysis of prion disease of the brain

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102674/1/msb200912.pd

The HUPO Human Proteome Project (HPP), a Global Health Research Collaboration

The global Human Proteome Project (HPP) was announced by the Human Proteome Organization (HUPO) at the 2010 World Congress of Proteomics in Sydney, Australia, and launched at the 2011 World Congress of Proteomics in Geneva, Switzerland, with analogies to the highly successful Human Genome Project. Extensive progress was reported at the September 2012 World Congress in Boston, USA. The HPP is designed to map the entire human proteome using available and emerging technologies.The HPP aims to create a molecular and biological foundation for improving health globally through better understanding of disease processes, more accurate diagnoses, and targets for more effective therapies and preventive interventions against many diseases. There are opportunities for individual investigators everywhere to access advanced datasets and to join HPP research teams

Prognostic Factors in Cancer, 3 rd edition. By M. K. Gospodarowicz, B. O'Sullivan, L. H. Sobin (Eds.)

No abstracts.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/55917/1/6385_ftp.pd

7 th HUPO World Congress of Proteomics: Launching the Second Phase of the HUPO Plasma Proteome Project (PPP-2) 16–20 August 2008, Amsterdam, The Netherlands

The HUPO Plasma Proteome Project new phase, PPP-2, held its initial workshop on 17 August, 2008, at the 7 th World Congress of Proteomics in Amsterdam. Technology platforms, data repositories, informatics, and engagement of research groups for the submission of major datasets were key topics. Plasma is expected to be the common pathway for biomarker development and application through collaboration and integration with other HUPO initiatives.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/61441/1/4_ftp.pd

THE HUPO Human Plasma Proteome Project

The Human Proteomics Organization (HUPO) Human Plasma Proteome Project (PPP) is a prominent example of the inherently collaborative nature of the overall community effort to characterize the proteome of humans in health and disease. The PPP Pilot Phase, called “Exploring the Human Plasma Proteome”, engaged 55 laboratories, four technical committees, and vendors and sponsors on an international scale. Among other outcomes, the PPP generated a Core Dataset of 3020 proteins identified with two or more peptides, fully accessible at EBI/PRIDE, ISB/PeptideAtlas, and University of Michigan websites, a rich resource for follow-on analyses. The PPP provided extensive annotation, correlation of number of peptides with protein concentrations measured by immunoassay, an algorithm for choice of a representative protein for multiple proteins matching a given peptide, and independent analyses from the raw spectra. The next phase of the PPP will emphasize standardized procedures for specimen handling, potent new technology platforms for discovery and for targeted proteomics, and robust informatics efforts, including comparative analyses of other biofluids.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/56177/1/769_ftp.pd

A well-characterised peak identification list of MALDI MS profile peaks for human blood serum

MALDI MS profiling, using easily available body fluids such as blood serum, has attracted considerable interest for its potential in clinical applications. Despite the numerous reports on MALDI MS profiling of human serum, there is only scarce information on the identity of the species making up these profiles, particularly in the mass range of larger peptides. Here, we provide a list of more than 90 entries of MALDI MS profile peak identities up to 10 kDa obtained from human blood serum. Various modifications such as phosphorylation were detected among the peptide identifications. The overlap with the few other MALDI MS peak lists published so far was found to be limited and hence our list significantly extends the number of identified peaks commonly found in MALDI MS profiling of human blood serum